Erratum: Department of Error (The Lancet (2017) 389(10072) (917–929) (S014067361730123X) (10.1016/S0140-6736(17)30123-X));First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

The Lancet

Volumn 389, Issue 10072, 2017, Pages 917-929

  Soria, Jean Charles ^a,b   Tan, Daniel S W ^c   Chiari, Rita ^d   Wu, Yi Long ^e   Paz Ares, Luis ^f   Wolf, Juergen ^g   Geater, Sarayut L ^h   Orlov, Sergey ⁱ   Cortinovis, Diego ^j   Yu, Chong Jen ^k   Hochmair, Maximillian ^l   Cortot, Alexis B ^m   Tsai, Chun Ming ⁿ   Moro Sibilot, Denis ^o   Campelo, Rosario G ^p   McCulloch, Tracey ^q   Sen, Paramita ^q   Dugan, Margaret ^q   Pantano, Serafino ^q   Branle, Fabrice ^q   Massacesi, Cristian ^q   de Castro, Gilberto ^r   more..

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f Structural Biology and Biocomputing Programme   (Spain)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h Songklanagarind Hospital   (Thailand)

ⁱ PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^j SAN GERARDO HOSPITAL   (Italy)

^k NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^l Otto Wagner Spital ^*  (Austria)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^o HÔPITAL MICHALLON   (France)

^p HOSPITAL JUAN CANALEJO   (Spain)

^q NOVARTIS PHARMA AG   (Switzerland)

^r UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CERITINIB; CISPLATIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; PEMETREXED; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GENE REARRANGEMENT; HEADACHE; HUMAN; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONCARDIAC CHEST PAIN; OPEN STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF RADIOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEMETREXED; PYRIMIDINES; SULFONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85010189205     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30603-7     Document Type: Erratum

References (26)

1. 1 Soda, M, Choi, YL, Enomoto, M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
2. 2 Shaw, AT, Yeap, BY, Mino-Kenudson, M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
3. 3 Solomon, BJ, Mok, T, Kim, DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
4. 4 Katayama, R, Shaw, AT, Khan, TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med, 4, 2012, 120ra17.
5. 5 Otterson, GA, Riely, GJ, Shaw, AT, et al. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. J Clin Oncol, 30(suppl), 2012 abstract 7600.
6. 6 Solomon, BJ, Cappuzzo, F, Felip, E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 34 (2016), 2858–2865.
7. 7 Friboulet, L, Li, N, Katayama, R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 (2014), 662–663.
8. 8 Zykadia prescribing information, 2014, Novartis AG, Basel https://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf (accessed June 23, 2016).
9. 9 Shaw, AT, Kim, DW, Mehra, R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
10. 10 Kim, DW, Mehra, R, Tan, DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17 (2016), 452–463.
11. 11 Felip, E, Orlov, S, Park, K, et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol, 27(suppl 6), 2016 abstract 1208O.
12. 12 Scagliotti, GV, Kortsik, C, Dark, GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11 (2005), 690–696.
13. 13 Scagliotti, GV, Parikh, P, von Pawel, J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543–3551.
14. 14 Ciuleanu, T, Brodowicz, T, Zielinski, C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009), 1432–1440.
15. 15 Paz-Ares, L, de Marinis, F, Dediu, M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13 (2012), 247–255.
16. 16 Paz-Ares, LG, de Marinis, F, Dediu, M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31 (2013), 2895–2902.
17. 17 Hong, Y, Passos, VQ, Huang, PH, Lau, YY, Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. J Clin Pharmacol, 2016, 10.1002/jcph.849 published online Dec 6.
18. 18 Camidge, DR, Kono, SA, Lu, X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6 (2011), 774–780.
19. 19 Lee, JO, Kim, TM, Lee, SH, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 6 (2011), 1474–1480.
20. 20 Zhang, I, Zaorsky, NG, Palmer, JD, Mehra, R, Lu, B, Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16 (2015), e510–e521.
21. 21 Hida T, Nokihara H, Kondo M, et al. Randomised phase 3 trial of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lancet (in press).
22. 22 Gettinger, SN, Bazhenova, LA, Langer, CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 1683–1696.
23. 23 ALECENSA prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf (accessed Jan 18, 2017).
24. 24 Dziadziuszko R, Kim D-W, Bearz A, et al. Phase 1 study of ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in ALK+ metastatic NSCLC. Presented at the World Conference on Lung Cancer; Vienna, Austria; Dec 4–7, 2016. Abstract number P3.02a-036.
25. 25 Kim Y, Hida T, Nokihara H, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). Presented at the World Conference on Lung Cancer; Vienna, Austria; Dec 4–7, 2016. Abstract number MA07.03.
26. 26 Peters, S, Mok, TSK, Perol, M, et al. Randomised, multicentre, phase III, open-label study of alectinib vs crizotinib in treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced NSCLC (ALEX study). Ann Oncol, 25(suppl 4), 2014 abstract 1334TiP.